Breast cancer is a multifactorial disease that develops as a result of interactions among genetic, environm ental, and hormona l factors. Multiple genetic derangem ents are believed to be involved in the pathogenes is of breast cancer, including the inactivation of tumor suppressor genes and/or the disregulation of proto-onco genes. Age, hormones, and environme ntal factors further in uence these genetic derangeme nts. Spontaneous and chemically induced animal models of breast cancer have been limited in their usefulness. The advent of targeted gene mutations has allowed for a more speci c exploratio n of the pathogenes is of breast cancer by creating mouse models that mimic single or multiple gene alterations found in huma n mam mary tumors. The genes targeted in these models include mouse mamm ary tumor integration sites and genes that encode for growth regulators, signal transduction proteins, cell cycle proteins, and cell matrix proteinases. In this review, I summarize tum or morphology and the relevance of each model to the pathogenes is and progression of human breast cancer. These m odels have great potential for elucidating the m ultistep process of mam mary gland carcinogen esis and for contributing to the identi cation of novel therapeutic targets.
INTRODUCTION
Breast cancer is the second leading cause of cancer death in wom en. It is estimated that 1 in 8 women will be diagnosed with breast cancer. Breast cancer is a multifactorial disease that develops as a result of interactions among genetic, environmental, and hormonal factors. The known endocrine and reproductive factors that increase a wom an's risk for developing breast cancer include early age of menarche, nulliparity, age of rst full-term pregnancy, and late menopause (9) . Estrogen replacem ent and steroidal and nonsteroidal estrogens are also associated with increased incidence of cancer and increased risks for development of the disease (124) .
Environmental factors associated with an increase risk for the developm ent of breast cancer include high-fat diet, alcohol consum ption (33, 68, 73, 98) , radiation exposure (43, 80, 82) , and chemical exposure (34) . Radiation exposure serves as an initiating event in the mammary gland of prepubertal and pubertal women (43, 80, 82) . At these tim es, the mamm ary gland is most susceptible to carcinogenic stimuli. About 34 chemicals tested by the National Toxicology Program, including halogenated hydrocarbons, aromatic amino/nitro compounds, and epoxide-forming compounds, were associated with an in-creased incidence of m amm ary gland tum ors in animal models (34) . These environmental chem icals were frequently mutagenic, and genetic damage was implicated as a m echanism of mamm ary carcinogenesis (34) .
Developing an understanding of the m echanistic impact of the genetic, environmental, and hormonal in uences on the initiation and progression of cancer has been a m ajor driving force of breast cancer research. One of the keys to deciphering the pathogenesis of mammary gland carcinogenesis is to rst understand how a multitude of hormones, growth factors, and regulatory signals contribute to normal mammary gland developm ent and then to determ ine what alterations have occurred in human breast tumors.
The comparative pathology of rodent and human mammary glands has been thoroughly reviewed (20, 104) .The most com mon morphology for hum an breast cancer is invasive ductal carcinoma, which arises from ductal carcinom a in situ. Mammary tum ors are believed to arise from the term inal ductular lobular unit in humans and from the rodent counterpart, the terminal end buds. Rodent mammary tum or m odels have been created in an attempt to reproduce the m orphologic and m echanistic characteristics of human breast cancer.
Animal models of spontaneous and chemically induced mammary gland carcinogenesis have provided some insight into the pathogenesis of breast cancer but do not faithfully mimic the pathology or biological behavior of human breast cancer. The advent of targeted gene m utations in rodent models has signi cantly contributed to our knowledge of the pathogenesis of human breast cancer. The ability to reproduce single and multiple gene alterations found in human breast tum ors has also yielded models that more closely re ect the human condition.
There is no single model that best mimics the pathology and m echanistic deregulation seen in breast cancer. Each model provides a small portion of the puzzle, which helps to clarify the com plex interactions associated with the heterogeneous population of cells in the norm al m ammary gland. These m odels enable the researcher to examine individual or combinations of perturbations that lead to the initiation and progression of breast cancer. The mechanistic insight gained from these genetically engineered rodent m odels has helped to advance novel therapeutics and chemotherapy strategies.
This overview includes a summary of the important pathologic features and contributions of genetically engineered rodent m odels of mammary gland carcinogenesis created over the last 20 years. Particular emphasis is placed on the characteristic tumor morphology, relevance to hum an breast cancer, and mechanistic contributions to the elucidation of the initiation and progression of breast cancer.
H ISTO R IC N ON -G EN ETIC A LLY E NG IN EER E D
ANIMAL MODELS A variety of in vivo system s have been used to elucidate the underlying mechanisms of breast cancer initiation and progression. Initial in vivo m odels included speci c mouse strains, such as A, GR, BR6, C3H, DBA, and RIII, that are predisposed to spontaneous m ammary tumors. The study of the tumorigenesis in these mouse strains led to the discovery of the mouse mammary tumor virus (M MTV) (88, 117) . The study of M MTV-infected mice contributed important information to the pathogenesis of rodent mammary carcinogenesis (17) .
MM TV is a slow, transforming retrovirus. Multiple cycles of pregnancy and lactation are required to facilitate tumorigenesis. Tumorigenesis occurs because of insertion of proviral DNA into the host DNA, which activates a variety of cellular oncogenes. These oncogenes activated by insertional mutagenesis were initially identi ed as int genes. They are now known to be oncogenes from the WNT, broblast growth factor, and Notch gene families (eg, Wnt-1, int-2/fgf-3, int-3/Notch 4) and genes associated with translational modi cation (eg, int-6) (16, 17) . Mamm ary tumors that develop as a result of insertional mutagenesis have speci c morphologic characteristics. Morphologically, the tumors are described as acinar (Dunn type A) or solid/cystic (Dunn type B) (109) and do not t the common morphology of human tum ors. Furtherm ore, the molecular alterations such as overexpression of W nt-1 have not been found in human breast tumors.
The classic models of chemically induced m ammary gland carcinogenesis, using chemicals such as 7,12-diethylbenzanthracene, produce hyperplastic alveolar nodules (HAN) in mice and broadenocarcinom as in rats (105, 117, 132) . Mutation of the ras oncogene is a characteristic m olecular alteration associated with the chemically induced models. However, ras m utations are associated with tum or progression rather than initiation and tumor maintenance (18, 62) . Although chemically induced models provide important insights into m amm ary tumor biology, they only model lim ited aspects of human breast cancer. These investigations and research with other viral oncogenes (eg, v-myc, v-ras, v-neu) laid the ground work for mouse models with targeted gene mutations.
GENETICALLY ENGINEERED MODELS
Over the past 20 years, rodent m odels with targeted gene mutations and deletions have been created based on the genetic alterations found in human breast tumors in an effort to mimic the hum an disease. The initiation and progression of breast cancer involves multiple genetic alterations that lead to the disregulation of the growth, differentiation, and apoptotic pathways that are responsible for the exquisitely orchestrated process of m ammary gland development. The genetic alterations include germline and/or som atic mutations of tumor suppressor genes and gene ampli cation and/or overexpression of a variety of proto-oncogenes. Targeted gene deletions or m utations provide the tools to study tumorigenesis in the absence of speci c tumor suppressor genes. Transgenic mouse mamm ary models give investigators the ability to introduce foreign DNA into the mouse genom e to promote tissue-speci c overexpression of an oncogene to determine the effects on tumorigenesis. Com bination models created using these techniques help reveal the interactions among multiple genes, as seen in bitransgenic m odels and gene-null or gene-de cient m odels combined with a transgenic m odel.
The effects and phenotypic expression of these m olecular alterations on mammary tumorigenesis are in uenced by the background strain used to create the model and by the prom oter. The effect of the genetics of the background strain on the phenotype has been documented in many models (31) . The background strain of the model is an important variable that contributes to differences in tumor morphology and tumor latency seen in genetically engineered mamm ary tumor m odels (100) . The prom oters used to target expression of the transgenes to the mamm ary gland can also alter the tumor m orphology and phenotype of the model.
Tissue-speci c expression is driven by prom oter sequences predominantly found in mamm ary speci c viruses and proteins. MM TV-driven expression is often sporadic throughout the mammary gland and other tissues such as the salivary gland and reproductive tissues. This sporadic expression and the variation in levels of expression contribute to what is described as the stochastic nature of many of the mammary tum or m odels where the MM TV prom oter drives transgene expression. The long terminal repeat (LTR) of MM TV carries response elem ents for glucocorticoids, progesterone, and androgen (5) . MM TV-promoted transgene expression is in uenced by estrous cycles in the virgin m ammary RODENT M AM MARY TUMOR M ODELS gland, and expression in the adult mammary gland is augmented by pregnancy (5) .
W hey acidic protein (WAP) and beta lactoglobulin (BLG) promoters direct mammary gland-speci c expression during midpregnancy and lactation. The milk proteins WAP and BLG are hormonally regulated by prolactin, estrogen, hydrocortisone, and insulin (3). Metallothionine directs expression to most epithelial cells. The C3(1) prom oter, a subunit of the rat prostate steroid binding protein originally used to target the prostate, has also been found to direct expression to the distal mammary duct epithelium and the terminal ductular lobular unit (45) .
At a recent sym posium, a system of nom enclature for m am m ar y tu m ors of genetically en gin eered m od els (GEM) was proposed (21) . Mamm ary tumors were categorized based on descriptive morphology instead of histologic origin because limited information is available on the tum or initiation and progression in the m odels that were reviewed. In addition, 4 broad categories for classifying mammary tumor models were proposed: non-genetically engineered models (non-GE M ), GEMtransgene speci c, GEM -Dunn's classi cation, and GEMunique phenotype. However, these classi cations do not preclude encountering tum or types typical of another category. For exam ple, the transgene-speci c m odels could also have tum or phenotypes in uenced by the background strain of the m ice or the promoter used. In the following overview of GEM, I use the descriptive m orphologic term inology suggested by the Annapolis committee if the m odel was reviewed at the sym posium. In all other morphologic descriptions of the tumors, the terminology is that used by the original researchers.
Gene-De cient/Gene-Null Models
Loss of heterozygosity, indicated by the loss or deletion of 1 of an individual's inherited chromosomal alleles, is a comm on genetic alteration in hum an breast cancer (24, 59, 67) . Mutations in tumor suppressor genes are frequently associated with loss of heterozygosity. TP53, retinoblastom a (Rb), and the breast cancer susceptibility genes, BRCA1 and BRCA2, are the tumor suppressor genes known to be involved in human breast cancer. Germline m utations of the TP53 gene, as found in the Li-Fraumeni syndrom e, are associated with an increased risk of breast cancer (46, 77) . Rb m utations are found in 7-30% and p53 mutations are found in 20 -40% of human breast cancers (81) .
The discovery of the genes responsible for familial breast cancer, BRCA1 and BRCA2, helped fuel the exploration into how genetic derangem ents act solely or in concert with environmental and horm onal stimulation to cause breast cancer. BRCA1 and BRCA2 tum or suppressor genes are believed to have multiple functions involving, DNA repair, cell cycle control, and transcriptional regulation. BRCA1 and BRCA2 mutations cause genom ic instability, resulting in the inactivation of other tum or suppressor genes or the activation of oncogenes, leading to tumor form ation. Recently, it has been estimated that 40 -50% of wom en with a familial histor y of breast cancer (22) and as high as 17% of women in the general population (78, 86) have a m utation in BRCA1 or BRCA2. Women who carr y m utations in the BRCA1 gene have an increased risk for the development of early onset breast and ovarian cancers (38) . BRCA2 germ -line m utations predispose both men and women to the developm ent of breast cancer (121) . Only a few som atic BRCA1 and BRCA2 m utations have been identi ed (65, 123) . BRCA1 and BRCA2 mutations are often associated with loss of p53 in human breast cancer (23) .
The embryonic and early postnatal death seen in Rb, TP53, BRCA1, and BRCA2 knockout m ice necessitates alternative approaches to studying how the loss of these proteins contributes to mammary tumorigenesis (44, 51, 54, 72, 74, 76) . One approach is the cre-lox system , where there is tissue-speci c targeted disruption of a gene (110) . A mouse strain is created with a speci c gene anked by lox p sites. Another mouse strain is created that expresses cre-recombinase, which targets the lox p sites and is driven by a tissue-speci c prom oter. The combination results in mice that have the targeted gene disrupted or deleted in a particular tissue. For example, BRCA1 conditional mutants carr y a BRCA1 null allele, a BRCA1 conditional allele with Lox p sites, and either a WAP or M MTV prom oter enhancing cre-recom binase expression (136) . Targeting cre-recombinase expression to the m amm ary gland allows for normal fetal development. Mammary-speci c disruption of BRCA1 resulted in restricted ductal development, mamm ary hyperplasia by 2-10 m onths, and a variety of m ammary tumors by 10 -13 months (136) . Conditional BRCA1 mutants combined with a p53 heterozygote demonstrate decreased tumor latency (136) . Epithelial transplant experiments with p53 null mamm ary tissue (57) and tissue-speci c expression of oncogenes using the avian leukosis virus system (37) are other methods being used.
Knockout m odels of hormone receptors, such as estrogen receptor knockout (ERKO), prolactin receptor knockout (PrLKO), progesterone receptor knockout (PRKO), and transcription factor knockouts (Stat5a null and Stat5b null) have contributed to our understanding of the functional roles of these receptors in mammary gland developm ent. These models are not directly associated with mammary tumorigenesis but provide a useful backdrop for deciphering cooperativity or interactions among a variety of oncogenes frequently overexpressed or ampli ed in human breast cancer.
Transgenic Models
There is an ever-growing list of transgenic, bitransgenic, and other genetically engineered combination m odels that are used to explore the role of growth factors, growth factor receptors, signal transduction proteins, cell cycle proteins, and cell matrix proteinases in mamm ary gland carcinogenesis. Cardiff et al (21) noted a few features that were com mon to the transgenic m ouse m amm ary models that they reviewed: 1) transgene overexpression can contribute to tumorigenesis but is often not the only alteration that leads to tum origenesis; 2) tum or latency and phenotype can be affected by the genetics of the background strain, the prom oter, and the level of transgene expression; and 3) transgenic m odels develop a variety of tum or phenotypes that do not t into the classical morphology schemes as outlined by Dunn (109) .
Virus-Induced Mammary Tumorigenesis. The involvement of growth factors such as int-2/fgf3 ( broblast growth factor), signal transduction proteins such as c-Src and Ha-ras, and transcription factors such as c-m yc in breast cancer dev elop m en t w as initially discov ered through the research of virus-induced tumorigenesis. Several retroviruses and DNA viruses have been used to create transgenic m amm ary tumor models.
MMTV-Induced Genes. Insertion sites for the MMTV, which include the Wnt genes Wnt-1 (int-1), Wnt 3, and wnt10b, the Notch genes NOTCH 4/int-3, and the broblast growth factor genes int-2/fgf3, hst-1/fgf4, and fgf8, are all implicated in mouse mammary tumorigenesis (88, 117) . A few of these genes are implicated in human mamm ary carcinogenesis based on transgenic mouse models developed with the MMTV promoter and alteration of these genes in hum an breast tum ors. For example, int-2/fgf3 is ampli ed in 15-20% of hum an breast cancers (35, 36) . Gene ampli cation is not associated with elevation in mRNA levels or protein. Int-2/fgf3 is a member of the broblast growth family of proteins, which act as m itogens, chem oattractants, and mediators of cellular differentiation (30, 81) . In the rodent, int-2 is norm ally expressed during early developm ent but is not expressed in the adult mammary gland (30, 81) . MM TV int-2 transgenic mice develop characteristic hyperplastic lesions with cellular atypia, categorized as mammary intraepithelial neoplasia (MIN) (21) . Mamm ary tumors are rare, with a latency period of up to 18 months (83) . The function of int-2 in normal human m amm ary gland is unknown, but it may ser ve as a biomarker for activation of a nearby oncogene or a prognostic indicator for tumor aggressiveness and recurrence (36, 81) .
Another exam ple of a MM TV insertion site that provides insight into the possible com parative molecular mechanisms of mammary carcinogenesis is Wnt-1. This gene is not overexpressed in human breast cancer. However, other W nt family m embers, such as Wnt-2, -4, -5A, -7B, and -10B, are elevated in human breast cancers (10) . The Wnt genes regulate cellular proliferation, cell morphology, cell m otility, and cell fate (25) and are expressed during normal developm ent of the mouse mammary gland. Similar Wnt genes are found in the human m ammary gland (10) . Wnt-1 is one of the major sites of proviral insertion for MM TV, and its role in mammary carcinogenesis has recently been reviewed (71) . In carcinomas of the M MTV-infected C3H mouse, 70% of the proviral insertions are at the Wnt-1 locus. W nt-1 is a secreted glycoprotein associated with the extracellular m atrix and the cell membrane. MMTV-promoted W nt-1 transgenic mice develop mammary hyperplasia by 8 weeks of age. Dunn type adenocarcinomas develop by 1 year of age in 15% of the m ales and in 100% of the females (125) . Tumors from Wnt-1 transgenic mice are typically glandular or acinar. However, Dunn type B solid tumors also develop, presumably under the in uence of MMTV promoter (personal observation). Several W nt-1 com bination models have demonstrated cooperative interaction with p53 and broblast growth factor-3 (fgf3) and hormonal independence (71) . Com bination m odels of Wnt-1 crossed with p53 null and W nt-1 crossed with MMTV fgf-3 mice result in accelerated tumor form ation (32, 63) . In addition, other W nt-1/estrogen receptor combination models with ER -null mice (ERKO -) and progesterone receptor null (PRKO) show that W nt-1-induced hyperplasia and neoplasia are independent of hormonal stimulation (12) .
The W nt signaling pathway is responsible for the stabilization and accumulation of intracellular -catenin in mamm ary epithelial cells (40, 90) . Wnt members capable of cellular transformation in vitro (Wnt-1, -2, -3, -3a, -6 , -7a) dem onstrate elevated -catenin levels (114) . -Catenin binds and activates Lef/Tcf transcription factor, which in turn m odulates the expression of genes such as c-myc (25) . Further investigations into the W nt signaling pathway may indicate links between the Wnt pathway and other proteins involved in mammary carcinogenesis. The W nt pathway may provide a key to novel therapeutics or chemotherapeutic strategies to combat human breast cancer.
Polyoma Middle T. Polyoma middle T is a small DNA papovavirus that encodes an oncogene, polyoma middle tumor antigen (PyMTA). PyMTA binds signal transduction proteins such as Src fam ily, phosphoinositol 3 kinase (PI3), and ras (26) . Although PyMTA is not associated with breast cancer in hum ans, the signaling proteins that it binds are altered in hum an breast cancer (5, 28) . Expression of polyoma m iddle T in mamm ary tumors of M MTV PyMTA mice is also associated with increased c-m yc levels (5, 28, 47) . Altered c-myc expression is another characteristic of human breast tum ors. In M MTV LTR PyM TA m ice, m ultifocal adenocarcinomas develop in 100% of the females by 5 weeks of age (47) . Combination m odels with prolactin-de cient mice (PrLKO), which have normal primary ductal branching but m inim al branching, dem on strate slo w ed tu m or growth. In addition, PrL heterozygotes develop tum ors 30% faster than do PrLKO m ice when com bined with mice overexpressing PyM TA (126) . Transgenic m ice expressing one of the downstream effectors of PyMTA, Src, dem onstrate impaired m ammary epithelial development, mamm ary hyperplasia, and scirrhous adenocarcinoma (131) .
Simian Virus 40. A third viral oncogene, simian virus 40 (SV40), inhibits p53 and Rb protein. SV40 is a papovavirus that encodes for and expresses SV40 large T antigen (SV40 T ag) when integrated into host DNA. SV40 T ag indirectly induces cell transformation and neoplasia by binding and functionally inactivating p53 and proteins within the retinoblastom a family, eg, pRb, p107, and p130.
Transgenic SV40 T ag m odels using WAP and C(3)1 promoters have similar tum or morphology but different tumor latency because of the in uences of background strain or other modi cations (Table 1 ). These models also dem onstrate ampli cation of Ki-ras and increased expression of cell cycle proteins and regulators of apoptosis (45, 70) .
Extracellular Matrix Proteins. Stromal cell-epithelial cell interactions play an integral part in the m ultistep pro- cess of mamm ary carcinogenesis. Metalloproteinases degrade extracellular m atrix substrates, release cell surface molecules such as E-cadherin, and activate other metalloproteinases and serine kinases (119) . Metalloproteinases regulate and facilitate mammary tumor progression through their role in angiogenesis, invasion, and metastasis (85) . Epithelial and stromal cells in hum an breast tum ors express a variety of m etalloproteinases such as stromelysin-1 and strom elysin-3, which are expressed in the stroma, matrilysin, which is expressed in the epithelium, and gelatinase, which is expressed in both (85). Stromelysin-1/MM P3 is normally expressed in stromal cells throughout mammary development, with maximal expression during postlactational involution (119) . Matrilysin is expressed in the mamm ary gland of adult cycling female mice (103) . Three groups have created transgenic mice expressing stromelysin-1 and matrilysin (134) ( Table 2 ). Combination models dem onstrate that matrilysin works cooperatively with c-neu. Fifty percent of the bitransgenic matrilysin and c-neu m ice develop characteristic solid nodular tum ors by 27 weeks of age compared with 40 weeks in the M MTV c-neu controls (102) . Stromelysin-1 m ay interact with the wnt/ -catenin/c-myc pathway. Sternlicht et al (118) proposed that stromelysin-1 degrades E-cadherin, resulting in the release of bound -catenin, thus implicating the wnt/ -catenin/c-myc pathway in tumorigenesis. As with the Wnt-1 model, the increase in intracellular -catenin results in -catenin binding and stimulation of LEF/Tcf. LEF/Tcf are transcription factors that stimulate the transcription of c-myc and other genes.
G row th Fa ctors a nd G ro w th F acto r R eceptors. Growth factors play an integral part in mammary gland development. Dysregulated growth factors or their downstream effectors are implicated in mammary gland carcinogenesis. Members of the broblast growth factor fam ily and m embers of the epiderm al and insulin-like growth factors and growth factor receptors are frequently overexpressed in human breast carcinom as (93, 94, 106) .
Insulin-Like Growth Factors: Insulin-like growth factor (IGF-I), the binding proteins, and IGF-I receptor (IGF-IR) are all produced locally in the mammary gland and play an important role in mamm ary gland development and m ammary carcinogenesis (122, 135, 137) . IGF-I and IGF -II are the ligands for the IGF-I receptor. In the mouse mammary gland, IGF-I plays an essential role in terminal end bud formation and ductal morphogenesis as a mediator of growth hormone action (101) . IGF-I is expressed in the terminal end buds and stroma throughout pubertal mammary gland development, with expression in the stroma throughout pregnancy and upregulation in the alveolar and duct epithelial cells during the latter half of pregnancy (101) . IGF-II and IGF -IR are expressed in the term inal end buds and duct and alveolar epithelium throughout pubertal development and pregnancy (135) .
In humans, IGF -I and IGF-II are mitogenic and promote cell survival by inhibiting apoptosis in norm al breast epithelial and cancerous cell lines. IGF-I is increased in serum of wom en with breast cancer (91) . In addition, IGF-II is frequently expressed in the strom a of invasive hum an breast cancer (39) . In contrast, IGF -II is not expressed in the stroma of benign lesions (89) . IGF-IR is overexpressed in 30 -40% of human breast cancers (94) . Overexpression is associated with increased levels of IGF -IR and increased function and signi es a poor prognosis (122) . In several mouse m odels, overexpression of various components of the IGF pathway has resulted in mammary tumor formation and other histologic changes correlated with the function of the ligands, the receptor, and downstream effectors of the IGF pathway.
Transgenic mouse models developed to study the IGF pathway demonstrate abnorm al mammary development and develop mamm ary tumors (Table 3 ). In the combination m odel WAP des(1-3)IGF-1/p53-172R -H, tum or latency was reduced to 7-8 m onths (50) . AKT-1 is a protein serine kinase associated with antiapoptotic and proliferative pathways activated by IGF-I. This kinase similarly activates the signaling pathway of the epidermal growth factor receptor, erbB2 (26) . Transgenic mice that overexpress AKT-1 develop mammary ductal hyperplasia with num erous end buds (1) .
Epidermal Growth Factors and Growth Factor Receptor Family: Transforming growth factor
(TGF ) and Neu differentiation factor (heregulin) are ligands that bind m embers of the epiderm al growth factor receptor (EGFR) fam ily. EGFR binding initiates signals for cell replication through a variety of signaling m olecules, including protein kinase A, RAS/Raf/MAP kinase pathway, Jak-Stat pathway, and c-Src (53) . TGF is normally expressed in the basal epithelial cells and the term inal cells of the end buds in the m ouse and in human m ammary epithelial cells during pregnancy (99) . There is increased expression but not gene ampli cation in 40 -70% of primary human breast tumors (3) .
Several mouse m odels overexpressing TGF develop alveolar hyperplasia and a spectrum of tumors. The most com mon tum or type is glandular adenocarcinom as, with tumor latencies that range from 6 to 16 months (Table  4 ). Although not seen in every model, delayed involution of the mamm ary gland is a comm on developmental abnorm ality (53) . Cyclin D1 expression is increased in tumors from WAP TGF m ice. In the WAP TGF /Stat 5a knockout com bination model, there is increased apoptosis, enhanced involution, and increased tumor latency (53) .
ErbB2/Her2/neu is a m ember of the EGFR family of class 1 receptor tyrosine kinases, which includes EGFR/ erbB1, erbB3/Her3, and erbB4/Her4 (81) . EGFR was originally discovered as a viral oncogene activated by avian erythroblastosis retrovirus. ErbB2 was originally cloned from hum an breast and gastric carcinoma. The rat neu gene was discovered in chemically induced neuroblastoma and contained a single point mutation, which allowed for an amino acid substitution in the transmembrane dom ain (96) .
The c-erbB2 gene is ampli ed or the protein is overexpressed in 20 -30% of m ammary carcinom as, 40 -50% of ductal carcinomas in situ (DCIS) and 90% of the comedo type DCIS (19, 96, 106) . Overexpression of erbB2 is associated with invasive breast cancers, m etastasis, and a poor prognosis (96, 133) . In 30% of human breast carcinomas, expression of neu/erbB2 is associated with mutant p53 (52) . C-erbB2 is normally expressed at low levels in a number of hum an secretor y epithelial cells (106) . Gene ampli cation and overexpression of erbB2 in human breast cancer is not associated with a point mutation, as seen in rat neu.
Several groups have created rodent models using an MMTV prom oter that overexpress either a point-mutated rat neu (activated neu) or a wild-type neu/erbB2 and result in a transgene-speci c tum or m orphology ( Table 5 ). The m ouse hom ologue of mutated hum an p53, p53-172 R-H, under the in uence of a WAP promoter in com bination with c-neu/ErbB2 works cooperatively to decrease tumor latency (69) .
Neu/erbB2 signals through the ras/MAP kinase pathway to stimulate the transcription of c-myc, c-fos, and cjun (96) . Consequently, ras signals several downstream regulators to coordinate its function as regulator of cell proliferation, transformation, and differentiation and promoter of cell survival. ErbB2 also activates AKT-1 in the PI3 pathway (26) . Both the ras and PI3 pathways lead to the promotion of cell survival by inhibiting apoptotic signals (26) . In addition to ras and PI3, erbB2 m ay interact with Src signaling proteins and transcription factors in the Stat family (26) . However, the exact mechanism of how erbB2 signal transduction leads to cell transformation is unknown. Signal Transduction Proteins. Alterations of signal transduction pathways are implicated in the carcinogenesis of numerous tissue types. The molecular analysis of hum an m amm ary tumors and tumors from animal m odels has further highlighted the role of a variety of signal transduction proteins in carcinogenesis. Several signal transduction proteins, which are used as transgenes in genetically engineered models, have already been discussed, including PyMTA, W nt-1, Src, and AKT-1. Ras is another signal transduction protein that has been used to study mammary carcinogenesis. The ras gene encodes a family of guanine trinucleotide-binding proteins that are localized to the inner face of the plasma membrane. Ras proteins (p21ras) mediate cellular proliferation signals from stimulated growth factor receptors, as described with erbB-2 (3, 26) . The point-m utated ras gene encodes for a constitutively activated p21ras, which leads to loss of cell cycle regulation, stimulates cell proliferation, and suppresses apoptosis (29) . Activated ras oncogenes are not frequently detected in hum an breast cancer. However, a study of m olecular alterations in human invasive ductal carcinomas dem onstrates ras overexpression is associated with allelic loss or overexpression of p53, erbB2 amplication or overexpression, and aneuploidy (116) . Three different groups have created transgenic m odels to study the role of Ha-ras in mammary carcinogenesis (4, 87, 115) (Table 6 ). Studies using com bination m odels with ras, myc, and p53 knockout m ice demonstrate that on-cogene expression can affect the response to chem otherapeutic agents (8) .
Cell Cycle Regulators. The overexpression of the upstream regulators, ie, the growth factor and growth factor receptors and their signaling proteins (ras, src, etc) ultimately leads to alterations in the expression of cell cycle proteins and transcription factors. Cyclin D1, c-m yc, and P53 are prime examples of cell cycle proteins and transcription factors that are altered in hum an breast cancers. The role of other cell cycle proteins in m amm ary gland carcinogenesis, such as cyclin E and mdm2, have also been explored (Table 7) .
Cyclin D1: Cyclin D1 is one of the regulators of the Rb gene, which is a tumor suppressor gene involved in cell cycle regulation (6, 14) . Progression through the G1 phase of the cell cycle is dependent on cyclins D and E. Maximum levels of cyclin D occur in m id-G1 phase. Cyclin D forms complexes with cdk4 and cdk6. Cyclin E is expressed near the G1/S boundary and com plexes with cdk2. Expression of cyclin D1 is controlled by extracellular signals, such as growth factors and growth factor receptors.
In the mamm ary gland cyclin D1 plays a critical role in pregnancy-induced proliferation of m ammary epithelium. Cyclin D1 protein is overexpressed in 50% of human breast cancers (129) . The cyclin D1 gene is amplied in 15-20% of hum an breast cancers and in 10% of DCIS (64) . Cyclin D1 overexpression is present without gene ampli cation in DCIS of intermediate or poorly differentiated histologic phenotype and estrogen receptor positivity (127) . MMTVcyclin D1 mice develop mammary hyperplasia and papillary adenocarcinom a by 18 months of age (129) ( Table 7) . c-M yc: c-M yc is a nuclear transcription factor that het- (55) . c-M yc expression in the m ammary gland is norm ally present during pregnancy-related proliferation and involution. Disregulation of c-myc expression is a comm on feature of many hum an cancers, and this protein is frequently overexpressed in hum an breast cancer (60) . Although the c-myc gene is ampli ed in 20% and rearranged in 5% of hum an breast cancers, c-myc protein is overexpressed in 45-70% human breast cancers (84, 128) . Overexpression of c-myc is believed to play a role in tumor progression rather than in initiation (11) . Three separate groups using either an M MTV or WAP promoter have created mouse models expressing c-myc (108, 112, 120) (Table 7) . Several bitransgenic models have been m ade with c-myc, including WAP -c-myc/ WAP-TGF , MM TV-c-myc/MT-TGF , M MTV-c-m yc/ Ha-ras, and M MTV-c-m yc/WAP bcl-2 (55, 56, 108, 112, 120) . c-Myc works synergistically with TGF and Haras to decrease tumor latency. Dual expression of bcl-2, the antiapoptotic protein, and c-m yc, which promotes apoptosis, leads to acceleration of tum origenesis.
THE IMPACT OF M OUSE MAMMARY TUMOR MODELS ON
DRUG DISCOVERY Genetically engineered models (GEM) have been instrumental in elucidating new targets for therapeutic inter ventions and evaluating chemotherapeutic strategies. These models have been com bined with dietary manipulations and chemical carcinogens to explore the roles of these factors in combination with various m olecular alterations. For example, erbB2 transgenic mice on the low -protein, high-ber, low -fat National Toxicology Program diet dem onstrate delayed tumor growth com pared with mice on other high-protein, high-fat diets (95) . GEM are also being used to develop novel chemotherapeutic and cancer prevention strategies. There are studies under way by Steve Hursting using the P53/W nt-1 model and by Jeffrey Green using the C3(1)SV40 T ag m odel.
Several key therapeutic targets have emerged from the study of GEM expressing c-myc, c-ras, c-neu, and matrix metalloproteinase transgenes (2, 41) . c-Myc overexpression is frequently found in the downstream pathways of many of genetically engineered mamm ary m odels (eg, ras, erbB-2, and W nt-1). Antisense oligonucleotides, directed against c-myc have been developed to inhibit cell proliferation and decrease c-myc expression (130) . Antireceptor antibodies against speci c epitopes on the ex-tracellular dom ain of erbB2 (HER2) have also been developed (42) . Anti-HER2 antibodies promote the formation of HER2 heterodimers, thus preventing dimerization with HER3 or HER4 and inhibiting tum or growth (66) . Although, the exact m echanism of how antibodies inhibit tumor growth in unknown, Le et al (66) demonstrated that anti-HER2 antibody caused growth arrest in the G1 phase of the cell cycle, preventing progression of G1 to S, decreased levels of cdk2, cyclin E, and cdk 6, and decreased cdk2-cyclin E-associated kinase activity.
In addition to being associated with human m ammary cancer, ras has emerged as a signi cant signal transducer that plays a role in tumorigenesis in several of the growth factor/growth factor receptor m odels, the polyom a middle T, and Src models. Ras signal transduction is dependent on m embrane localization of the ras protein. Ras prenylatio n is critical for p ro per m em b ran e localization (58, 111) . Farnesyl protein transferase inhibitors target farnesyl transferase, which catalyzes the rst posttranslational m odi cation step, the farnesylation of cysteine residues near the carboxy terminus of ras (ie, prenylation).
Metalloproteinases have an expanding role in tumor progression, invasion, and metastasis. In addition, they may play a role in the W nt cell-signaling pathway. Metalloproteinase inhibitors have been created to inhibit the actions of single or multiple m etalloproteinases by acting as broad-spectrum or selective competitive inhibitors (85) .
SUMMARY
By analyzing the genetic alterations in hum an breast cancer patients and developing m odel systems to determine their signi cance, scientists are better able to unravel the steps involved in tum or initiation and progression. Genetically engineered rodent models have brought us several steps closer to understanding the m olecular mechanisms underlying breast cancer. There are many overlapping pathways and cooperative interactions between oncogenes. However, the characterization of these models is still in its infancy. Further elucidation of these models will advance the developm ent of novel therapeutic drugs to ght and prevent breast cancer. ACKNOWLEDGMENTS I thank Drs M. Sternlicht, E. Schm idt, C. Deng, E. Sandgren, and C. Graham for allowing m e to use histology images from their rodent models in m y oral presen-RODENT M AM MARY TUMOR M ODELS tation. I give special thanks to Ulrike Wagner for m aking the images available to m e. A valuable resource for these and other images can be found at HistoBank: The Interactive Histology Atlas, created by Ulrike Wagner, Jai Evans, and Christopher Santos. This web site is located at http://histology.nih.gov.
